Similar articles for PMID: 27390321

Year	Number of Results
2002	2
2006	1
2007	1
2010	3
2011	4
2012	2
2013	2
2014	7
2015	11
2016	12
2017	9
2018	6
2019	6
2020	2
2022	0

1

Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas.

Daniels D, Guez D, Last D, Hoffmann C, Nass D, Talianski A, Tsarfaty G, Salomon S, Kanner AA, Blumenthal DT, Bokstein F, Harnof S, Yekutieli D, Zamir S, Cohen ZR, Zach L, Mardor Y. Daniels D, et al. AJNR Am J Neuroradiol. 2016 Nov;37(11):2003-2009. doi: 10.3174/ajnr.A4866. Epub 2016 Jul 7. AJNR Am J Neuroradiol. 2016. PMID: 27390321 Free PMC article.

2

Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab.

Bahrami N, Piccioni D, Karunamuni R, Chang YH, White N, Delfanti R, Seibert TM, Hattangadi-Gluth JA, Dale A, Farid N, McDonald CR. Bahrami N, et al. AJNR Am J Neuroradiol. 2018 Jun;39(6):1017-1024. doi: 10.3174/ajnr.A5620. Epub 2018 Apr 5. AJNR Am J Neuroradiol. 2018. PMID: 29622553 Free PMC article.

3

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.

Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Kickingereder P, et al. Neuro Oncol. 2015 Aug;17(8):1139-47. doi: 10.1093/neuonc/nov028. Epub 2015 Mar 9. Neuro Oncol. 2015. PMID: 25754089 Free PMC article.

4

Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.

Server A, Kulle B, Gadmar ØB, Josefsen R, Kumar T, Nakstad PH. Server A, et al. Eur J Radiol. 2011 Nov;80(2):462-70. doi: 10.1016/j.ejrad.2010.07.017. Epub 2010 Aug 13. Eur J Radiol. 2011. PMID: 20708868

5

Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.

Piludu F, Marzi S, Pace A, Villani V, Fabi A, Carapella CM, Terrenato I, Antenucci A, Vidiri A. Piludu F, et al. Neuroradiology. 2015 Dec;57(12):1269-80. doi: 10.1007/s00234-015-1582-9. Epub 2015 Sep 12. Neuroradiology. 2015. PMID: 26364181 Clinical Trial.

6

Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.

Seeger A, Braun C, Skardelly M, Paulsen F, Schittenhelm J, Ernemann U, Bisdas S. Seeger A, et al. Acad Radiol. 2013 Dec;20(12):1557-65. doi: 10.1016/j.acra.2013.09.003. Acad Radiol. 2013. PMID: 24200483

7

Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.

Artzi M, Bokstein F, Blumenthal DT, Aizenstein O, Liberman G, Corn BW, Ben Bashat D. Artzi M, et al. Eur J Radiol. 2014 Jul;83(7):1250-1256. doi: 10.1016/j.ejrad.2014.03.026. Epub 2014 Apr 12. Eur J Radiol. 2014. PMID: 24809637 Clinical Trial.

8

Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.

Park JE, Kim HS, Park SY, Jung SC, Kim JH, Heo HY. Park JE, et al. Radiology. 2020 May;295(2):397-406. doi: 10.1148/radiol.2020191376. Epub 2020 Mar 10. Radiology. 2020. PMID: 32154775

9

Correlation of Tumor Immunohistochemistry with Dynamic Contrast-Enhanced and DSC-MRI Parameters in Patients with Gliomas.

Nguyen TB, Cron GO, Bezzina K, Perdrizet K, Torres CH, Chakraborty S, Woulfe J, Jansen GH, Thornhill RE, Zanette B, Cameron IG. Nguyen TB, et al. AJNR Am J Neuroradiol. 2016 Dec;37(12):2217-2223. doi: 10.3174/ajnr.A4908. Epub 2016 Sep 1. AJNR Am J Neuroradiol. 2016. PMID: 27585700 Free PMC article.

10

The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.

Heinzel A, Müller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM, Galldiks N. Heinzel A, et al. J Nucl Med. 2013 Aug;54(8):1217-22. doi: 10.2967/jnumed.113.120089. Epub 2013 Jun 19. J Nucl Med. 2013. PMID: 23785172 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed